Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT
Lebwohl M, Papp K, Ehst B, Lomaga M, Rich P, Strober B, Armstrong A, López Pinto J, Kaspar M, Deherder D, Wang M, Vender R. Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT. SKIN The Journal Of Cutaneous Medicine 2024, 8: s431. DOI: 10.25251/skin.8.supp.431.Peer-Reviewed Original Research